Navigation Links
Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
Date:12/1/2009

ROCKVILLE, Md., Dec. 1 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the waiting period has expired under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to Vanda's agreement, dated October 12, 2009, with Novartis Pharma AG, and that the agreement is now effective. Expiration of the waiting period, and the resulting effectiveness of the agreement, triggers an upfront payment to Vanda of $200 million.

Pursuant to the agreement, Novartis will have exclusive commercialization rights to Fanapt(TM) in the U.S. and Canada. Novartis will be responsible for the further clinical development activities in these territories, including the development and commercialization of a long-acting injectable (or depot) formulation of Fanapt(TM). Vanda will retain rights to commercialize Fanapt(TM) oral and depot formulations outside the U.S. and Canada, but Novartis has the option to enter into discussions with Vanda to co-commercialize Fanapt(TM) or receive sales royalties outside the U.S. and Canada.

About Vanda

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com.

SOURCE Vanda Pharmaceuticals Inc.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
(Date:1/14/2014)... PORT WASHINGTON, New York , January 14, ... the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, ... sales growth for the fourth straight year.   ... of exposure for pharmacy technicians, pharmacists, nurses and ...
(Date:1/14/2014)... FRANCISCO , Jan. 14, 2014 Spark Therapeutics , ... for its most advanced clinical program, a Phase 3 study for ... gene. Spark,s CEO, Jeffrey D. Marrazzo , is presenting this ... Healthcare Conference in San Francisco . Marrazzo said ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... officials in FDA,s Office of New Drugs (OND), the ... a cardiovascular outcomes trial (CVOT) for Contrave® that would ... 2011. Orexigen believes that these design requirements are reasonable ...
... CLEVELAND, Sept. 20, 2011 Dr. Melisa Estes, who is ... suffer from chronic knee pain. She recently began incorporating a ... nerve stimulation, also known as TENS, sends electrical stimulation to ... signals from reaching the brain, and that reduces pain. ...
Cached Medicine Technology:Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5Knee Pain Control - No Drugs - Doctor Used 2
(Date:4/18/2014)... A new medical-testing device is being prepped to ... could improve diagnosis of certain diseases in remote ... a series of investigations aboard the International Space ... uses the space-tested concept of capillary flow to ... , David Kelso, Ph.D., a researcher at Northwestern ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... , MONDAY, March 14 (HealthDay News) -- Women may ... a diet rich in two types of B vitamins, a ... and riboflavin (B2) in their food significantly reduced their risk ... fortified cereals, whole grains, beans and nuts, and researchers said ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, March ... that is, a pediatrician or nurse they see regularly who offers ... dental needs met, new research finds. Yet it,s the sickest ... and require the most care -- who are less likely to ...
... the globe are making headway in fighting communicable diseases ... research from the Frederick S. Pardee Center for International ... School of International Studies. The center ... volumes that focus on human progress in which researchers ...
... human studies of an oral drug regimen to prevent HIV ... in HIV incidence, but a number of issues require additional ... a large scale, according to an article in AIDS ... Mary Ann Liebert, Inc. ( www.liebertpub.com ). The article is ...
... Research and Education recently received a five year, $3.7 ... and Agriculture to fund a project aimed at preventing ... to teach mothers simple yet authoritative strategies to promote ... The grant was awarded to Jenifer Orlet Fisher, associate ...
... ,Scientists at the National Institute of Allergy and Infectious ... have shown how the O157:H7 strain of Escherichia ... host immune response. The bacterium secretes a protein called ... alter specific immune responses. This process not only helps ...
Cached Medicine News:Health News:Diets Rich in Vitamin B May Help Prevent PMS, Study Finds 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 3Health News:DU researchers find that headway being made fighting communicable diseases globally 2Health News:DU researchers find that headway being made fighting communicable diseases globally 3Health News:Early success of anti-HIV preventive oral drug regimen is promising, but questions remain 2Health News:Temple receives $3.7 million to study parenting styles' effect on childhood obesity 2
The Panorama Central Station includes bi-directional communication with Datascope bedside monitors, optional 72 hours of disclosure and a touch screen user interface....
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Developed in a Microsoft Windows environment, MedInformatix provides physician practices a Computerized Patient Record (CPR) with a Practice Management System (PMS) that is both integrated and design...
Medicine Products: